Skip to main content
. 2020 Mar 2;41(7):911–927. doi: 10.1038/s41401-020-0372-z

Fig. 5.

Fig. 5

PVAX immunotherapy for both recurrent and metastatic 4T1 tumors. a Schematic depiction of the manufacture of PVAX for cancer immunotherapy. b Average and individual tumor growth curves of recurrent 4T1 xenografts in mice treated with different formulations. c Survival curves of the mice bearing 4T1 recurrent tumors. d Average tumor growth curves of the distant tumors treated with different formulations. e Tumor-free percentages of the abscopal tumor. Reprinted with permission from [195]